Multidisciplinary molecular tumor boards (MTB) are already well established in many comprehensive cancer centers and play an important role in the individual treatment planning for cancer patients. Comprehensive genomic profiling of tumor tissue based on next-generation sequencing is currently performed for diagnostic and mainly predictive testing. If somatic genomic variants are identified, which are suspected to be pathogenic germline variants (PGVs), MTB propose genetic counseling and germline DNA testing. Commonly used comprehensive genomic profiling approaches of tumor tissue do not include a matched germline DNA control. Therefore, the detection of PGVs could be only predicted based on the content of tumor cells (CTC) in selected tumor area (%) and variant allele frequency score (%). For conclusion, the role of a medical geneticist is essential in these cases. The overall prevalence of PGVs in patients with pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) is approximately 10%. In this single-center study, we present 37 patients with PDAC and 48 patients with CRC who were presented at MTB and tested using the large combined DNA/RNA sequencing panel. Content of tumor cells and variant allele frequency scores were evaluated in all tested patients. In case of suspicion of PGV and no previous genetic testing based on the standard guidelines, genetic counseling was recommended regardless of age, sex, and family history. In the PDAC subgroup, five patients were recommended by MTB for genetic counseling based on suspicious genetic findings. Based on a medical geneticist's decision, germline DNA sequencing was performed in four of these cases, and all of them tested positive for PGV in the following genes: ATM, ATM, BRCA1, and BRCA2. In the CRC subgroup, no PGV was confirmed in the two patients genetically tested based on the MTB recommendations. Furthermore, we present data from our center's registry of patients with PDAC and CRC who underwent genetic counseling and germline DNA testing based on the standard screening criteria. Our data confirm that comprehensive genomic profiling of tumor tissue can identify patients with hereditary forms of PDAC, who could remain unidentified by standard screening for hereditary forms of cancer.

Department of Biology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

Department of Molecular Medicine Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Pathology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

Department of Surgery University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Rawla P, Sunkara T, Gaduputi V.. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 2019;10:10–27. https://doi.org/10.14740/wjon1166 PubMed DOI PMC

Siegel RL, Miller KD, Fuchs HE, et al.Cancer statistics, 2021. CA Cancer J Clin 2021;71:7–33. https://doi.org/10.3322/caac.21654 PubMed DOI

Kardosh A, Lichtensztajn DY, Gubens MA, et al.Long-term survivors of pancreatic cancer. Pancreas 2018;47:958–66. https://doi.org/10.1097/MPA.0000000000001133 PubMed DOI PMC

Conroy T, Castan F, Lopez A, et al.; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol 2022;8:1571–8. https://doi.org/10.1001/jamaoncol.2022.3829 PubMed DOI PMC

Strobel O, Lorenz P, Hinz U, et al.Actual five-year survival after upfront resection for pancreatic ductal adenocarcinoma: Who beats the odds? Ann Surg 2022;275:962–71. https://doi.org/10.1097/SLA.0000000000004147 PubMed DOI

Versteijne E, van Dam JL, Suker M, et al.; Dutch Pancreatic Cancer Group. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial. J Clin Oncol 2022;40:1220–30. https://doi.org/10.1200/JCO.21.02233 PubMed DOI

Conroy T, Desseigne F, Ychou M, et al.; Groupe Tumeurs Digestives of Unicancer. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817–25. https://doi.org/10.1056/NEJMoa1011923 PubMed DOI

van Veldhuisen E, van den Oord C, Brada LJ, et al.; Dutch Pancreatic Cancer Group and International Collaborative Group on Locally Advanced Pancreatic Cancer. Locally advanced pancreatic cancer: work-up, staging, and local intervention strategies. Cancers (Basel). 2019;11:976. https://doi.org/10.3390/cancers11070976 PubMed DOI PMC

Morgan E, Arnold M, Gini A, et al.Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 2023;72:338–44. https://doi.org/10.1136/gutjnl-2022-327736 PubMed DOI

Siegel RL, Wagle NS, Cercek A, et al.Colorectal cancer statistics, 2023. CA Cancer J Clin 2023;73:233–54. https://doi.org/10.3322/caac.21772 PubMed DOI

Hernandez Dominguez O, Yilmaz S, Steele SR.. Stage IV colorectal cancer management and treatment. J Clin Med 2023;12:2072. https://doi.org/10.3390/jcm12052072 PubMed DOI PMC

Väyrynen V, Wirta EV, Seppälä T, et al.Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study. BJS Open 2020;4:685–92. https://doi.org/10.1002/bjs5.50299 PubMed DOI PMC

Cancer of the Colon and Rectum - Cancer Stat Facts. SEER. https://seer.cancer.gov/statfacts/html/colorect.html (19 October 2023, date last accessed).

Heeke AL, Pishvaian MJ, Lynce F, et al.Prevalence of homologous recombination–related gene mutations across multiple cancer types. JCO Precis Oncol 2018;2:1–13. https://doi.org/10.1200/PO.17.00286 PubMed DOI PMC

Dudley B, Karloski E, Monzon FA, et al.Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy. Cancer 2018;124:1691–700. https://doi.org/10.1002/cncr.31242 PubMed DOI

Uson PLS, Riegert-Johnson D, Boardman L, et al.Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multicenter prospective study. Clin Gastroenterol Hepatol 2022;20:e508–28. https://doi.org/10.1016/j.cgh.2021.04.013 PubMed DOI

Holter S, Borgida A, Dodd A, et al.Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 2015;33:3124–9. https://doi.org/10.1200/JCO.2014.59.7401 PubMed DOI

Samadder NJ, Riegert-Johnson D, Boardman L, et al.Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol 2021;7:230–7. https://doi.org/10.1001/jamaoncol.2020.6252 PubMed DOI PMC

Pishvaian MJ, Bender RJ, Halverson D, et al.Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative. Clin Cancer Res 2018;24:5018–27. https://doi.org/10.1158/1078-0432.CCR-18-0531 PubMed DOI

Yekedüz E, Akbulut H, Utkan G, et al.Genomic landscape of actionable mutations in primary and metastatic tissues of colon adenocarcinoma. Cureus 2022;14:e24175. https://doi.org/10.7759/cureus.24175 PubMed DOI PMC

Tempero MA, Malafa MP, Al-Hawary M, et al.Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021;19:439–57. https://doi.org/10.6004/jnccn.2021.0017 PubMed DOI

Kurian AW, Abrahamse P, Furgal A, et al.Germline genetic testing after cancer diagnosis. JAMA 2023;330:43–51. https://doi.org/10.1001/jama.2023.9526 PubMed DOI PMC

Vasen HF, Watson P, Mecklin JP, et al.New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453–6. https://doi.org/10.1016/s0016-5085(99)70510-x PubMed DOI

Strickler JH, Satake H, George TJ, et al.Sotorasib in KRAS p.G12C-Mutated advanced pancreatic cancer. N Engl J Med 2023;388:33–43. https://doi.org/10.1056/NEJMoa2208470 PubMed DOI PMC

Yaeger R, Weiss J, Pelster MS, et al.Adagrasib with or without Cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med 2023;388:44–54. https://doi.org/10.1056/NEJMoa2212419 PubMed DOI PMC

Koltun ES, Rice MA, Gustafson WC, et al.Abstract 3597: direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor. Cancer Res 2022;82:3597–3597. https://doi.org/10.1158/1538-7445.AM2022-3597 DOI

Tavberidze N, Zhang W.. HER2 (ERBB2) alterations in colorectal cancers. Human Pathol Rep 2022;28:300628. https://doi.org/10.1016/j.hpr.2022.300628 DOI

Chou A, Waddell N, Cowley MJ, et al.Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med 2013;5:78. https://doi.org/10.1186/gm482 PubMed DOI PMC

Strickler JH, Cercek A, Siena S, et al.; MOUNTAINEER investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol 2023;24:496–508. https://doi.org/10.1016/S1470-2045(23)00150-X PubMed DOI

Yoshino T, Di Bartolomeo M, Raghav K, et al.; DESTINY-CRC01 investigators. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun 2023;14:3332. https://doi.org/10.1038/s41467-023-38032-4 PubMed DOI PMC

Meric-Bernstam F, Makker V, Oaknin A, et al.Efficacy and safety of trastuzumab deruxtecan in patients With HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2023;42:47–58. https://doi.org/10.1200/JCO.23.02005 PubMed DOI PMC

Harder J, Ihorst G, Heinemann V, et al.Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012;106:1033–8. https://doi.org/10.1038/bjc.2012.18 PubMed DOI PMC

Caputo F, Santini C, Bardasi C, et al.BRAF-mutated colorectal cancer: clinical and molecular insights. Int J Mol Sci 2019;20:5369. https://doi.org/10.3390/ijms20215369 PubMed DOI PMC

Sasankan S, Rebuck L, Darrah G, et al.Metastatic pancreatic cancer with BRAF and P53 mutations: case report of therapeutic response to doublet targeted therapy. Case Rep Oncol 2020;13:1239–43. https://doi.org/10.1159/000510096 PubMed DOI PMC

Tian J, Chen JH, Chao SX, et al.Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat Med 2023;29:458–66. https://doi.org/10.1038/s41591-022-02181-8 PubMed DOI PMC

Subbiah V, Kreitman RJ, Wainberg ZA, et al.Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 2023;29:1103–12. https://doi.org/10.1038/s41591-023-02321-8 PubMed DOI PMC

Butt SUR, Mejias A, Morelli C, et al.BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series. Cancer Chemother Pharmacol 2021;87:437–41. https://doi.org/10.1007/s00280-021-04234-0 PubMed DOI

Kopetz S, Grothey A, Yaeger R, et al.Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 2019;381:1632–43. https://doi.org/10.1056/NEJMoa1908075 PubMed DOI

Moynahan ME, Pierce AJ, Jasin M.. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001;7:263–72. https://doi.org/10.1016/s1097-2765(01)00174-5 PubMed DOI

Moynahan ME, Chiu JW, Koller BH, et al.Brca1 controls homology-directed DNA repair. Mol Cell 1999;4:511–8. https://doi.org/10.1016/s1097-2765(00)80202-6 PubMed DOI

Turner N, Tutt A, Ashworth A.. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 2004;4:814–9. https://doi.org/10.1038/nrc1457 PubMed DOI

Husain A, He G, Venkatraman ES, et al.BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998;58:1120–3. PubMed

O’Reilly EM, Lee JW, Zalupski M, et al.Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020;38:1378–88. https://doi.org/10.1200/JCO.19.02931 PubMed DOI PMC

Fogelman D, Sugar EA, Oliver G, et al.Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2015;76:489–98. https://doi.org/10.1007/s00280-015-2788-6 PubMed DOI PMC

Shroff RT, Hendifar A, McWilliams RR, et al.Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol 2018;2018:PO.17.00316. https://doi.org/10.1200/PO.17.00316 PubMed DOI PMC

Lee MS, Kopetz S.. Are Homologous recombination deficiency mutations relevant in colorectal cancer? JNCI 2021;114:176–8. https://doi.org/10.1093/jnci/djab170 PubMed DOI PMC

Allen MJ, Zhang A, Bavi P, et al.Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. J Clin Pathol 2023;76:158–65. https://doi.org/10.1136/jclinpath-2021-207781 PubMed DOI

Wang H, Li Z, Ou Q, et al.NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer Med 2022;11:2541–9. https://doi.org/10.1002/cam4.4561 PubMed DOI PMC

Bokemeyer C, Vassal G, Italiano A, et al.Impact of disease evolution on efficacy outcomes from larotrectinib in patients with locally advanced or metastatic tropomyosin receptor kinase fusion–positive solid tumors. JCO Precis Oncol 2021;5:PO.21.00089. https://doi.org/10.1200/PO.21.00089 PubMed DOI PMC

Luchini C, Brosens LAA, Wood LD, et al.Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut 2021;70:148–56. https://doi.org/10.1136/gutjnl-2020-320726 PubMed DOI PMC

Sinicrope FA, Sargent DJ.. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 2012;18:1506–12. https://doi.org/10.1158/1078-0432.CCR-11-1469 PubMed DOI PMC

Gian L, Lorena B, Cinzia A, et al.Microsatellite instability in colorectal cancer. Acta Biomed 2018;89:97–101. https://doi.org/10.23750/abm.v89i9-S.7960 PubMed DOI PMC

Weiss JM, Gupta S, Burke CA, et al.NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021. J Natl Compr Canc Netw 2021;19:1122–32. 10.1164/jnccn.2021.0048 PubMed DOI

André T, Shiu KK, Kim TW, et al.; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020;383:2207–18. https://doi.org/10.1056/NEJMoa2017699 PubMed DOI

Diaz LA, Shiu KK, Kim TW, et al.; KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022;23:659–70. https://doi.org/10.1016/S1470-2045(22)00197-8 PubMed DOI PMC

Marabelle A, Le DT, Ascierto PA, et al.Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020;38:1–10. https://doi.org/10.1200/JCO.19.02105 PubMed DOI PMC

Commentary: Special Issue: Current Understanding of Colorectal and Pancreatic Cancers